Equity Analysis /
United States of America

US : Acceleron Pharma Inc. - XLRN | More Bullish Than Ever Following Meeting With Management; Raising PT to $160

    Daniil Gataulin
    Daniil Gataulin

    Ph.D., Sr. Res. Assoc.

    19 January 2021
    Published byCGS-CIMB

    We caught up with Acceleron management last week to get an update on the ongoing Reblozyl launch, and sotatercept's PAH program. XLRN and partner BMS provided peak revenue guidance for Reblozyl of $4B by 2029 on a risk unadjusted basis. These bullish projections indicate to us that the ongoing laun